Insider Selling: Omada Health (NASDAQ:OMDA) CAO Sells $26,050.00 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CAO Craig Gracey sold 1,042 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $26,050.00. Following the transaction, the chief accounting officer directly owned 15,441 shares in the company, valued at approximately $386,025. This represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Craig Gracey also recently made the following trade(s):

• On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total value of $14,651.00.
• On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The stock was sold at an average price of $22.00, for a total value of $8,910.00.
• On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $21.00, for a total value of $43,743.00.
• On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total value of $41,680.00.
• On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $19.01, for a total value of $39,597.83.
• On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $18.00, for a total value of $37,494.00.
• On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48.

Omada Health Stock Performance

Omada Health stock traded down $0.17 during trading hours on Wednesday, reaching $23.84. 1,552,408 shares of the company’s stock traded hands, compared to its average volume of 1,274,695. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 476.80 and a beta of 1.73. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The firm’s 50 day moving average is $20.61 and its 200-day moving average is $16.32.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.10. The company had revenue of $87.83 million during the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. Analysts predict that Omada Health, Inc. will post -0.01 EPS for the current year.

Hedge Funds Weigh In On Omada Health

Several hedge funds and other institutional investors have recently made changes to their positions in OMDA. Quarry LP bought a new stake in Omada Health in the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. acquired a new stake in Omada Health during the fourth quarter worth approximately $32,000. Raymond James Financial Inc. bought a new position in shares of Omada Health in the second quarter worth $32,000. Inlight Wealth Management LLC acquired a new stake in Omada Health during the fourth quarter worth about $45,000. Finally, Versant Capital Management Inc raised its position in shares of Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares in the last quarter.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on OMDA. BTIG Research increased their price target on Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Company boosted their target price on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. BMO Capital Markets restated an “outperform” rating and issued a $24.00 price target on shares of Omada Health in a report on Friday, August 7th. Citizens Jmp increased their target price on Omada Health from $21.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Monday, July 20th. Finally, Robert W. Baird upped their price target on shares of Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.